Ocular Therapeutix (NASDAQ:OCUL) has commercially launched DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery, in U.S.
DEXTENZA is the first FDA-approved intracanalicular insert, that enables the delivery of drug to the surface of the eye, obviating the need for a burdensome, monthly regimen of steroid eye drops.
Shares are up 7% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.